Remarks {#Sec1}
=======

Since December 2019, a novel coronavirus (severe acute respiratory syndrome---coronavirus 2, SARS-CoV-2) has rapidly been transmitted around the world resulting in an acute respiratory illness pandemic. The clinical picture, coronavirus disease 2019 (COVID-19), has affected thousands of people so far and created an unprecedented strain on many health care systems.

Background {#Sec2}
==========

These recommendations aim to give guidance to physicians treating COVID-19 patients on their ICUs. Experiences from China and Italy, where we see a high case load, currently serve as our benchmark, while acknowledging that the pandemic is still in an early, dynamic stage and that experience and scientific evidence will grow \[[@CR1]\]. Comprehensive information on the pathogen and the trajectory of the pandemic is available online through the Robert Koch-Institut (RKI, [www.rki.de](http://www.rki.de)).

We strongly recommend a multidisciplinary approach while tackling the challenges that ICUs and hospitals encounter with the management and treatment of COVID-19 patients. Aside from intensive care physicians and nurses, infectious disease and infection control specialists need to be part of the team.

Transmission of SARS-CoV‑2 usually occurs via droplet infection during close contact. Therefore, a strict implementation of basic infection control measures such as hand hygiene and the use of personal protection equipment (PPE) are essential.

Specimens and testing {#Sec3}
=====================

The detection of SARS-CoV‑2 is carried out from a deep oropharyngeal swab or oropharyngeal lavage using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). A patient with a negative test should be retested if there is a high clinical suspicion that they contracted the virus. The swab might become negative in a later stage of the disease (pneumonia, ARDS) while there is still infectious viral shedding in the lower airways. A PCR of endotracheal aspirates might be helpful in those cases.

Clinical disease pattern {#Sec4}
========================

Patients usually present with fever and dry cough as key features of COVID-19. In 81% of the patients the disease takes a mild course, 14% of the patients become severely ill, and, approximately 5% of the patients become critically ill \[[@CR2]\]. Severe dyspnea with an increased work of breathing (respiratory rate \>30/min) and hypoxemic respiratory failure typically lead to admission to ICU. At that stage, bilateral pulmonary infiltrates can often be seen on imaging \[[@CR3]\]. Severely affected patients may develop ARDS or bacterial superinfection and septic shock. Further complications seen in those patients are myocardial dysfunction and arrhythmias as well as acute kidney failure. On average, it takes approximately 10 days from showing first symptoms to ICU admission \[[@CR4]\].

Laboratory changes {#Sec5}
==================

In 80% of COVID-19 patients there is apparent lymphocytopenia, and, in one third of those patients this is accompanied by leukopenia. Most of the patients have normal levels of procalcitonin. However, a bacterial superinfection might trigger a significant increase. C‑Reactive protein is usually elevated, where very high values seem to correlate with worse outcomes \[[@CR5]\]. Thrombocytopenia, and, an elevation of D‑dimers and lactate dehydrogenase (LDH) are found in approximately 40% of the patients. An increase in unspecific LDH, especially as high as or more than 400 IU/ml, seems to indicate a severe course of the disease. A small portion of patients also present with elevated troponin, of which the clinical implications are unknown.

Imaging {#Sec6}
=======

Conventional chest radiographs show bilateral infiltrates in COVID-19 patients treated on ICU. Even in early stages of the disease, computed tomography (CT) can reliably detect typical bilateral subpleural ground-glass opacities \[[@CR6]\] and consolidation of the lungs \[[@CR7]\]. However, due to the potential risks for health care workers and patients, we advise to only perform a CT in ICU patients when absolutely necessary for clinical decision making \[[@CR8]\]. Bedside imaging, like ultrasonography, should be preferred.

Infection control {#Sec7}
=================

Patients should preferably be treated in isolation rooms ideally with a functional anteroom for donning and doffing PPE. As the epidemic/pandemic progresses, isolation of patients in cohorts is reasonable. Patients with COVID-19 should only be seen and cared for by trained personnel who do not have contact to other non-COVID-19 patients. The number of people working or visiting at bedside should be kept to a minimum---this also includes implementation of restrictions to visits by family and friends.

Personnel working at bedside must strictly adhere to basic infection control measures such as hand hygiene and consequently follow instructions on the use of personal protection equipment (PPE). According to the RKI, correct PPE consists of an impervious gown, gloves, tight-fitting facemask (FFP2 or FFP3 or respirator in case of strong exposure to aerosols, e.g., bronchoscopy) as well as goggles. It is important to frequently train health care workers on structured donning and removing of PPE, especially on tight mask-fitting and sequential hand disinfection. Comprehensive recommendations on infection control (rooms, protection of personnel, disinfection, cleaning, waste handling and patient transport) can be found online on the website of the RKI \[[@CR9]\]. Local guidelines and standard procedures for hospitals should be implemented by a multidisciplinary expert panel.

Drugs {#Sec8}
=====

To date there is not enough data to recommend a specific antiviral treatment for COVID-19. Several drugs (hydroxychloroquine/chloroquine, lopinavir/ritonavir, camostat mesilate, remdesivir and others) have been considered as treatment options. We recommend to only use those options as part of compassionate use programs or approved study protocols after carefully evaluating risks and benefits for the individual patient \[[@CR10]\]. The University of Liverpool has published possible pharmacokinetic interactions of experimental COVID-19 therapies that might support decision making \[[@CR11]\].

Steroids should not routinely be used in ARDS patients as they seem to reduce viral clearance and promote opportunistic infections, e.g., fungal infections \[[@CR12]\]. Studies in SARS and influenza showed a disadvantage for patients treated with steroids. However, in septic shock refractory to fluids and vasopressors, low-dose hydrocortisone is still indicated \[[@CR13]\].

Antibiotics {#Sec9}
===========

As a principle, we recommend sampling of at least two blood cultures sets (aerobic and anaerobic at any one time) at the time of admission to ICU and whenever the patient worsens \[[@CR13]\]. In patients suspected to have a bacterial superinfection an empiric broad-spectrum antibiotic therapy should be started as soon as possible. A prophylactic antibiotic treatment is not recommended.

Management of acute hypoxemic respiratory failure {#Sec10}
=================================================

Fluid management should be handled restrictively, especially in cases with no signs of shock or tissue malperfusion, as fluid overload further impairs oxygenation.

The goal is to ascertain adequate oxygenation. We recommend aiming for S~p~O~2~ ≥90% \[[@CR14]\]. It is important to acknowledge that oxygen supplementation through high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) leads to aerosol formation. It is therefore absolutely necessary to make sure that HFNC and facemasks are fitted correctly to the patient \[[@CR15]\], and, that the medical personnel at bedside strictly adheres to PPE instructions. Noninvasive ventilation with a helmet should be preferred where available.

In general, we advise to be rather restrictive with HFNC and NIV in the context of COVID-19. In patients with severe hypoxemia (P~a~O~2~/F~i~O~2~ ≤200 mm Hg) we suggest performing early intubation and invasive mechanical ventilation. In any case, continuous monitoring and preparedness for urgent intubation are cornerstones in the treatment of COVID-19 patients with respiratory failure. A delay of intubation in patients failing NIV worsens outcome, and, any emergency intubation in this cohort puts medical professionals at risk and should be avoided.

Intubation and other procedures {#Sec11}
===============================

Airway procedures (intubation, bronchoscopy, open suction, bag ventilation, tracheostomy) should only be performed with appropriate airborne precautions PPE (including FFP2/FFP3 masks and goggles) if absolutely necessary due to the risk of aerosol formation. For invasive ventilation we recommend closed inline suction catheters. Any disconnection of the patient from the ventilator should be avoided to prevent lung decruitment and aerosolization. If necessary, the endotracheal tube should be clamped, and the ventilator disabled (to prevent aerosolization). Use of nebulizers is not recommended and use of metered dose inhalers are preferred where possible.

Intubation should be performed by the most experienced physician with a broad expertise in airway management. If possible, a rapid sequence induction without intermittent bag mask ventilation should be preferred to minimize aerosol formation \[[@CR16]\]. With using a video-laryngoscope for intubation the distance between physician and patient during intubation can be increased. To verify correct tube placement avoid using the stethoscope and use direct visualization and CO~2~ indicators or capnography.

In case of a cardiopulmonary arrest and subsequent cardiopulmonary resuscitation the medical team has to make sure PPE is still used correctly. Airway management needs to be performed quickly and the number of people at the bedside should be kept to a minimum if possible.

Invasive ventilation and adjuvant treatments {#Sec12}
============================================

In patients with ARDS, international guidelines recommend a tidal volume (TV) of ≤6 ml/kg ideal body weight and a plateau pressure of no more than 30 cm H~2~O. Positive end-expiratory pressure (PEEP) can be adjusted according to the ARDS network tables. Moderate and severe ARDS necessitates higher PEEP \[[@CR17]\].

In ARDS with a P~a~O~2~/F~i~O~2~ \<150 mm Hg prone positioning should be administered consistently for 16 h. If severe hypoxemia persists, prone positioning needs to be repeated.

As options for bridging in very severe cases inhaled NO, the administration of muscle relaxants and recruitment maneuvers may be considered.

Where available, in patients with severe ARDS and refractory hypoxemia (P~a~O~2/~F~i~O~2~ \<80 or 60 mm Hg) veno-venous extracorporeal membrane oxygenation (ECMO) may serve as a therapeutic option to stabilize gas exchange. As it is a very complex and resource intensive treatment, all other measures should have been exhausted before considering ECMO, and thorough risk--benefit consideration, including presumed patient goals, is warranted.

Management of ICU capacity {#Sec13}
==========================

The German ARDS-network and the working group *Respiratory Failure* within the *German Interdisciplinary Association of Critical Care and Emergency Medicine* (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin) in cooperation with the RKI have launched a website that provides an overview of currently available ICU beds in Germany (<https://www.intensivregister.de/#/intensivregister>).
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